Oculis to Participate in Upcoming Investor Conferences
MWN-AI** Summary
Oculis Holding AG, a biopharmaceutical company specializing in neuro-ophthalmology and ophthalmic diseases, has announced its participation in several investor conferences scheduled for March 2026. This comes at a crucial time as the company is on the verge of significant advancements in its late-stage clinical portfolio. The management team is set to provide updates on their innovative therapies that target substantial unmet medical needs in eye care.
Notably, Oculis' Privosegtor, part of the PIONEER program, has received breakthrough therapy designation for optic neuritis, with plans to address two optic neuropathies and target a significant U.S. market opportunity exceeding $7 billion. Additionally, Oculis is anticipating topline results from its OCS-01 diabetic macular edema (DME) Phase 3 trials by Q2 2026. Furthermore, the company is advancing Licaminlimab, a promising drug in a registrational trial aimed at developing a precision medicine approach for dry eye disease (DED).
The conferences will take place at various locations, including the Leerink Global Healthcare Conference in Miami, where Oculis' CEO, Riad Sherif, will deliver a presentation, and the LifeSci Capital Biotech Forum in New York City. One-on-one meetings will also be arranged for investors interested in learning more about Oculis' innovative strategies and potential for growth.
Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is well-funded and positioned to deliver pivotal clinical results that could redefine eye care treatments. The company's commitment to innovative, non-invasive therapies demonstrates its mission of improving sight and overall eye health. For more information about the company and its products, please visit www.oculis.com.
MWN-AI** Analysis
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) presents a compelling investment opportunity as it prepares to participate in several investor conferences in March 2026. With its robust pipeline targeting significant unmet medical needs in ophthalmology and neuro-ophthalmology, Oculis is strategically positioned to attract investor interest.
One of the key highlights is the breakthrough therapy designation of Privosegtor for optic neuritis under the PIONEER program. This innovative treatment could tap into a potential market exceeding $7 billion in the U.S. alone, underlining the substantial revenue prospects that could arise from successful commercial deployment. Furthermore, OCS-01 is scheduled to reveal topline results from its Phase 3 trials for diabetic macular edema (DME) in Q2 2026, offering the prospect of introducing a non-invasive treatment in a high-demand sector.
The precision medicine initiatives surrounding Licaminlimab demonstrate Oculis' commitment to innovation, particularly in the burgeoning field of genotype-targeted therapies for dry eye disease. These developments indicate a forward-thinking approach that could enhance Oculis' reputation as a leader in the biopharmaceutical field.
Considering Oculis' strong balance sheet and the potential for six pivotal readouts with existing funding, the company appears to have the necessary resources to drive these innovative treatments through to market. Such developments, paired with the company's management's track record, form a solid foundation for potential growth.
Investors should consider following Oculis closely during these presentations and Webcasts at conferences like the Leerink Global Healthcare Conference and LifeSci Capital Biotech Forum. Engaging in one-on-one meetings during these events can also provide deeper insights into Oculis’ strategic direction and investment potential. Overall, Oculis represents a strong growth opportunity in the biopharmaceutical landscape, meriting consideration for investment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor conferences in March.
Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: Privosegtor (PIONEER program) granted breakthrough therapy designation for optic neuritis (ON) as Oculis advances the registrational program in two optic neuropathies to address a potential market opportunity of $7B+ in the U.S. alone; OCS-01 (DIAMOND Phase 3 trials) topline results in diabetic macular edema (DME) on track for Q2 2026; Licaminlimab (PREDICT-1 registrational trial) being evaluated as the first genotype-based development program to drive precision medicine in dry eye disease (DED).
With a strong balance sheet and robust pipeline, Oculis is well-positioned to deliver 6 pivotal readouts with the current funding, to fulfil its mission to save sight and improve eye care with groundbreaking treatments.
Leerink Global Healthcare Conference
March 8-11, Miami, FL, USA
Company presentation by Riad Sherif, M.D., Chief Executive Officer, on March 10th, 10:40 AM ET.
Webcast link: Register here
Leerink Partners Mountain Meeting
March 22-25, Jackson Hole, WY, USA
Oculis management will participate in one-on-one meetings.
LifeSci Capital Biotech Forum
March 26, New York City, NY, USA
Oculis management will participate in one-on-one meetings.
The company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
Webcast links, when available, are posted to the Oculis website on the Events & Presentation page under the Investors & Media section.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNF? in registrational trial, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements and information. For example, statements regarding the development plans for Privosegtor, OCS-01, and Licaminlimab; the initiation, timing, progress and results of clinical trials of Privosegtor, OCS-01, and Licaminlimab; and Oculis’ research and development programs, regulatory and business strategy, future development plans, and management, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
FAQ**
What specific milestones does Oculis Holding AG OCS anticipate achieving in its PIONEER program for Privosegtor aimed at optic neuritis by the end of 2026?
2. How does Oculis Holding AG OCS plan to leverage breakthrough therapy designation for Privosegtor to penetrate the $7B+ U.S. market for optic neuropathies?
3. Can Oculis Holding AG OCS provide insights into the timeline for topline results from the DIAMOND Phase 3 trials for OCS-01 in diabetic macular edema?
4. In what ways does Oculis Holding AG OCS intend to differentiate Licaminlimab in the precision medicine landscape for dry eye disease during its ongoing registrational trial?
**MWN-AI FAQ is based on asking OpenAI questions about Oculis Holding AG (NASDAQ: OCS).
NASDAQ: OCS
OCS Trading
5.19% G/L:
$28.485 Last:
1,474,751 Volume:
$27.53 Open:
